Tumor News and Research

RSS

Shear-thinning biomaterial-based minimally invasive strategy for delivery of targeted immunotherapy

Researchers at the Terasaki Institute for Biomedical Innovation (TIBI) have developed and optimized a minimally invasive method for more targeted, efficient, and sustained delivery of immunotherapeutic treatments for cancer.

2 Aug 2022

TransCode and MD Anderson scientists collaborate to validate therapeutic and diagnostic candidates

The University of Texas MD Anderson Cancer Center and TransCode Therapeutics, Inc. today announced a strategic alliance to advance TransCode's pipeline of RNA-targeted oncology therapeutic and diagnostic candidates.

2 Aug 2022

The efficacy of honokiol in inhibiting SARS-CoV-2 replication in cell culture

Researchers evaluated the efficacy of honokiol in inhibiting SARS-CoV-2 replication in cell cultures.

2 Aug 2022

MD Anderson and Advanced Biology collaborate to host the virtual Cancer Neuroscience Symposium

The University of Texas MD Anderson Cancer Center will host the virtual Cancer Neuroscience Symposium Sept. 22-23, 2022, in collaboration with the journal Advanced Biology.

1 Aug 2022

What is the immunopathogenesis of pediatric COVID-19?

Researchers assessed the immunopathogenesis of COVID-19 infection in children.

1 Aug 2022

Decoy ACE2 receptors broadly neutralize SARS-CoV-2 variants

Researchers review current developments in preclinical studies associated with recombinant ACE2 decoy receptors against coronaviruses.

31 Jul 2022

Researchers use a tumor organoid system to examine bacterial effects on immunotherapy

Wake Forest Institute for Regenerative Medicine researchers are using a tumor organoid system to examine the effects of metabolites secreted by bacteria on a specialized immunotherapy – immune checkpoint blockage, a promising cancer treatment development – to determine why some patients don't respond or develop a resistance to the treatment over time.

29 Jul 2022

Tannins as therapeutic agents against SARS-CoV-2

Researchers reviewed tannins as therapeutic agents against SARS-CoV-2.

29 Jul 2022

Modifi Bio comes up with a new technology to combat cancer cells with DNA modification

Modifi Biosciences announced today that the journal Science has published a critical study validating the company's novel oncology platform based on new classes of molecules that exploit tumor-associated DNA repair defects through direct cancer cell DNA modification.

29 Jul 2022

New glioma drug may represent a paradigm for designing therapeutics exploiting specific DNA repair

A new class of glioma drugs exploits tumors that lack the DNA repair enzyme MGMT; the drugs lead to the generation of cytotoxic DNA and selectively kill tumor cells without the risk of resistance, researchers report.

29 Jul 2022

Novel targeted therapy may be an effective treatment option for neuroblastoma

New research from VCU Massey Cancer Center - published Thursday in Cell Reports - demonstrated that a novel targeted therapy could be an effective treatment option for a deadly pediatric cancer known as neuroblastoma.

28 Jul 2022

Transplant remains the standard of care for liver cancer patients, regardless of age

Physicians and researchers from UK HealthCare's Transplant Center and the University of Kentucky Markey Cancer Center conducted a study of patients over the age of 70 with a type of liver cancer called hepatocellular carcinoma (HCC) and how the outcomes of ablative treatments compare to liver transplants.

28 Jul 2022

New discovery may open the door to targeted treatments for two types of rhabdomyosarcoma

A gene that UVA Health researchers discovered is responsible for the deadliest type of brain tumor is also responsible for two forms of childhood cancer, the scientists have found.

28 Jul 2022

Repurposing an antipsychotic drug to treat various types of cancer

To treat some of the psychosis issues associated with Parkinson's disease, physicians often prescribe pimavanserin, an antipsychotic drug that acts within the brain to prevent hallucinations and delusions.

28 Jul 2022

The role of cellular or cytokine response and vaginal microbiome dysbiosis in the clearance, persistence, and recurrence of HPV infection

Researchers have reviewed the role of cytokine or cellular response and vaginal microbiome dysbiosis in the persistence, clearance, and recurrence of HPV infection

28 Jul 2022

Tumor News and Research

Shear-thinning biomaterial-based minimally invasive strategy for delivery of targeted immunotherapy

TransCode and MD Anderson scientists collaborate to validate therapeutic and diagnostic candidates

The efficacy of honokiol in inhibiting SARS-CoV-2 replication in cell culture

MD Anderson and Advanced Biology collaborate to host the virtual Cancer Neuroscience Symposium

What is the immunopathogenesis of pediatric COVID-19?

Decoy ACE2 receptors broadly neutralize SARS-CoV-2 variants

Researchers use a tumor organoid system to examine bacterial effects on immunotherapy

Tannins as therapeutic agents against SARS-CoV-2

Modifi Bio comes up with a new technology to combat cancer cells with DNA modification

New glioma drug may represent a paradigm for designing therapeutics exploiting specific DNA repair

Novel targeted therapy may be an effective treatment option for neuroblastoma

Transplant remains the standard of care for liver cancer patients, regardless of age

New discovery may open the door to targeted treatments for two types of rhabdomyosarcoma

Repurposing an antipsychotic drug to treat various types of cancer

The role of cellular or cytokine response and vaginal microbiome dysbiosis in the clearance, persistence, and recurrence of HPV infection

New ultra-thin photoacoustic endomicroscopy probe can be easily integrated with medical devices

Novel compound inhibits SARS-CoV-2 replication by binding a genome target

Creating a Microrobot to One Day Tackle Cancer

How COVID-19 affects the brain microvasculature

Scientists explore SARS-CoV-2 spike protein and platelet-activating factor

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News